Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.4652W HIGH $7.30
Volume
643.05 K
Value Traded
14.48 M
Short % Float
20.05%
Days to Cover
11.2
+1.9%Week
-19.54%1 Month
-27.53%3 Month
-37.85%6 Month
-75.03%5 Year
-75.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.31 B
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
898.82 M
Total Shares
325.83 M
Float Shares
274.37 M
Insiders
15.79%
Institutions
87.76%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TSHA Catalyst Timeline
Dated clinical, regulatory and corporate events for Taysha Gene Therapies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Taysha Gene Therapies, Inc.
377Total events
7Upcoming
70Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseTSHA-102Corporate
Taysha and Catalent expand partnership for commercial manufacturing support of TSHA-102
Rett syndromesource ↗
◆Oral PresentationTSHA-102Presentation
Establishing the Rett Syndrome Developmental Milestone Assessment (RS-DMA) as a Primary Endpoint for Interventional Studies (Company Hosted Symposium)
Rett syndromesource ↗
▲Enrollment CompleteTSHA-102Trial
Completion of dosing in ASPIRE trial (N=4) expected in July 2026
Rett syndromesource ↗
◆Oral PresentationTSHA-102Presentation
Safety and Efficacy Results from the REVEAL Part A Phase 1/2 Trial of TSHA-102 in Pediatric and Adolescent/Adult Cohorts
Rett syndromesource ↗
◆Poster PresentationTSHA-102Presentation
Superior Expression of Self-complementary AAV and Comparable Functionality of Mini and Full-length MECP2 Support the Design of TSHA-102 Gene Therapy for Rett Syndrome
Rett syndromesource ↗
◆Poster PresentationTSHA-102Presentation
The Developmental Plateau in Rett Syndrome: New Insights from the Natural History Study Inform Novel Interventional Study Designs
Rett syndromesource ↗
▼Equity OfferingCorporate
Proposed public offering of $200M common stock and pre-funded warrants
▲Enrollment CompleteTSHA-102Trial
Completed dosing of 17 patients in REVEAL pivotal trial
Rett syndromesource ↗
▲Full ResultsTSHA-102Clinical Data
Longer-term clinical data from Part A of REVEAL Phase 1/2 trials reported
Rett syndromesource ↗
●Oral PresentationTSHA-102Presentation
Conference call and webcast to discuss longer-term data
Rett syndromesource ↗
●Poster PresentationTSHA-102Presentation
Poster presentation at ASGCT 2026 Annual Meeting on May 14, 2026
Rett syndromesource ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Corporate Update Conference Call
▲FDA Feedback ReceivedTSHA-102FDA Meeting
FDA alignment reaffirmed on TSHA-102 BLA pathway including pivotal trial design, endpoints, and potential submission based on REVEAL 6-month interim analysis
Rett syndromesource ↗
▲Enrollment MilestoneTSHA-102Trial
Further advanced dosing in REVEAL pivotal trial; multiple patients dosed across multiple sites
Rett syndromesource ↗
●Enrollment UpdateTSHA-102Trial
Enrollment in ASPIRE trial ongoing across multiple clinical trial sites
Rett syndromesource ↗
▲Safety Data UpdateTSHA-102Clinical Data
No treatment-related SAEs or DLTs as of May 2026 data cutoff
Rett syndromesource ↗
▲PublicationPresentation
Peer-reviewed publication on lumbar IT dosing for gene therapy to CNS published in Frontiers in Medicine
◆Full ResultsTSHA-102Clinical Data
Update on longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials (n=12) expected in Q2 2026
Rett syndromesource ↗
▲Enrollment CompleteTSHA-102Trial
Completion of dosing in REVEAL pivotal trial expected in Q2 2026
Rett syndromesource ↗
▲Manufacturing MilestoneTSHA-102CMC / Inspection
Initiated BLA-enabling PPQ campaign for TSHA-102 in April 2026
Rett syndromesource ↗
◆Quarterly UpdateCorporate
Full-year 2025 financial results and corporate update conference call
▲First Patient DosedTSHA-102Trial
Dosed multiple Rett syndrome patients in REVEAL pivotal trial
Rett syndromesource ↗
▲IND ClearanceTSHA-102IND
FDA clearance to initiate ASPIRE trial in patients aged 2 to <4 years
Rett syndromesource ↗
▲FDA Feedback ReceivedTSHA-102FDA Meeting
FDA alignment on PPQ and comparability strategy for commercial TSHA-102 manufacturing
Rett syndromesource ↗
▲FDA Feedback ReceivedTSHA-102FDA Meeting
Written FDA alignment on ASPIRE trial data for BLA inclusion
Rett syndromesource ↗
◆Quarterly UpdateCorporate
Third Quarter 2025 Financial Results and Corporate Update Conference Call
▲Breakthrough Therapy DesignationTSHA-102Designation
TSHA-102 granted Breakthrough Therapy designation by FDA
Rett syndromesource ↗
▲FDA Feedback ReceivedTSHA-102FDA Meeting
Finalized FDA alignment on REVEAL pivotal trial protocol and SAP
Rett syndromesource ↗
▲Oral PresentationTSHA-102Presentation
Presented new supplemental analysis of Part A REVEAL data at CNS Annual Meeting
Rett syndromesource ↗
▲Partnership / LicenseTSHA-102Corporate
Regained full unencumbered rights to TSHA-102 Rett syndrome program
Rett syndromesource ↗
▲Partnership / LicenseTSHA-102Corporate
Regained full rights to TSHA-102 after Astellas option agreement expired
Rett syndromesource ↗
▲Oral PresentationTSHA-102Presentation
Presentation of supplemental data analysis from Part A of REVEAL Phase 1/2 trials at 54th CNS Annual Meeting
Rett syndromesource ↗
▲Breakthrough Therapy DesignationTSHA-102Designation
FDA granted Breakthrough Therapy designation for TSHA-102 in Rett syndrome
Rett syndromesource ↗
▲FDA Feedback ReceivedTSHA-102FDA Meeting
FDA alignment finalized on REVEAL pivotal trial protocol and SAP
Rett syndromesource ↗
▲First Patient DosedTSHA-102Trial
First patient dosing in REVEAL pivotal trial scheduled this quarter
Rett syndromesource ↗
◆Enrollment MilestoneTSHA-102Trial
Patient enrollment initiation for REVEAL pivotal trial expected in Q4 2025
Rett syndromesource ↗
●Enrollment UpdateTSHA-102Trial
Enrollment of additional patients expected to continue at multiple sites this quarter
Rett syndromesource ↗
▲Safety Data UpdateTSHA-102Clinical Data
TSHA-102 continues to be generally well tolerated with no treatment-related SAEs or DLTs in 12 patients as of October 2025 data cutoff
Rett syndromesource ↗
◆Topline ReadoutTSHA-102Clinical Data
Anticipates reporting new supplemental REVEAL Part A clinical data in Q4 2025
Rett syndromesource ↗
▲Runway Guidance UpdateCorporate
Cash runway extended into Q4 2025 due to program prioritization
▲Trial InitiationTSHA-102Trial
Commenced site activation for REVEAL pivotal trial
Rett syndromesource ↗
▲Oral PresentationTSHA-102Presentation
Part A data from REVEAL Phase 1/2 trials presented at IRSF Scientific Meeting
Rett syndromesource ↗
▲FDA Feedback ReceivedTSHA-102FDA Meeting
Received feedback from FDA on key design elements of REVEAL pivotal trial
Rett syndromesource ↗
▲Other Regulator MilestoneTSHA-102Ex-US Regulatory
Received No Objection Letter (NOL) from Health Canada
Rett syndromesource ↗
▲Safety Data UpdateTSHA-102Clinical Data
TSHA-102 generally well tolerated with no treatment-related SAEs or DLTs in 12 patients as of August 2025 data cutoff
Rett syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How TSHA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-15 | TSHA-102 | Phase 1/2 data presentation | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 86%
Micro Cap(rank 565 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TSHA-102 Gene therapyNCT06152237 | Rett Syndrome | Phase 3 | ACTIVE NOT_RECRUITING | 27 | Nov 2, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every TSHA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TSHA-102 BreakthroughFast TrackRMAT+2 | Rett syndrome | Phase 1/2 | 2026-06-22 | 100% of REVEAL Part A patients (N=12,6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102; 310 total functional gains demonstrated ≥12 months post-TSHA-102 (~26 per patient); 31 developmental milestones and 279 additional skill gains/improvementsRead More | Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett SyndromeRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nagendran SukumarDirector, Officer (President and Head of R&D) | Sell | -200,000 936,410 held | $6.24 | 07/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TSHA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 1.5 % (50 %) | 162.68 M | 23.89 M | 10.09% ( 2.19 M) |
TSHA Institutional Ownership Trends
TSHA Short Interest
Shares sold short, counted twice a month.
20.05%
Short % of Float
of tradable shares sold short
55.0M
Shares Sold Short
+7.0% vs prior count
11.2 Very high
Days to Cover
trading days of normal volume to buy every short share back
4.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TSHA ranks across every disease it competes in
Competitive Position is a premium feature
See how TSHA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTSHA News
TSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced the grant of restricted stock units and stock options to four new employees as part of its 2023 Inducement Plan. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), reflects the company's commitment to attract talent while focusing on advancing AAV-based gene therapies for severe CNS diseases. The stock options have a 10-year term and will vest over four years.
Read more →TSHATaysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies announced multiple encore presentations for its TSHA-102 program targeting Rett syndrome at the upcoming Child Neurology Society Annual Meeting. The presentations will showcase previously shared data and include an oral presentation on safety and efficacy results from the REVEAL trial. TSHA-102 is a gene therapy designed to address the genetic cause of Rett syndrome.
Read more →TSHATaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies has completed dosing in the REVEAL and ASPIRE trials for TSHA-102, targeting Rett syndrome. The company anticipates reporting topline data from a six-month interim analysis and receiving FDA feedback on the Biologics License Application submission pathway in the first half of 2027. TSHA-102 has shown good tolerance among participants.
Read more →TSHATaysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
Taysha Gene Therapies, Inc. will report its second quarter 2026 financial results on August 11, 2026, and host a conference call and webcast at 4:30 PM ET. The company focuses on AAV-based gene therapies for severe CNS diseases, with its lead program targeting Rett syndrome. An archived replay of the webcast will be available on its website.
Read more →TSHATaysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies has expanded its strategic partnership with Catalent to include future commercial manufacturing support for its TSHA-102 gene therapy, aimed at treating Rett Syndrome. This collaboration is expected to enhance Taysha's capabilities in bringing their gene therapy to market. The partnership signifies a commitment to advancing treatments for rare diseases.
Read more →TSHATaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies has announced multiple presentations at the 2026 IRSF Rett Syndrome Scientific Meeting, showcasing the TSHA-102 clinical program. Recent data from the REVEAL Part A trial indicates significant functional improvements over time in patients. The company is advancing its investigational gene therapy aimed at addressing the genetic cause of Rett syndrome.
Read more →TSHA▼ -10.5%on this newsshared move
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies has announced the pricing of a public offering of 32.5 million shares at $6.00 each, aiming to raise around $200 million. The offering includes pre-funded warrants for certain investors. The closing is anticipated on June 26, 2026, subject to standard conditions. Taysha focuses on AAV-based gene therapies for severe CNS diseases.
Read more →TSHA▼ -10.5%on this newsshared move
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The offering is intended to support the company's development of AAV-based gene therapies for severe CNS diseases. Jefferies, Goldman Sachs, Piper Sandler, and Cantor are managing the offering, which is subject to market conditions.
Read more →TSHATaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Taysha Gene Therapies has completed dosing in the REVEAL pivotal trial for TSHA-102, a gene therapy for Rett syndrome. The interim analysis shows that all patients achieved developmental milestones within 12 months post-treatment, with significant functional gains. The company plans to engage with the FDA regarding a Biologics License Application (BLA) submission in early 2027, following positive longer-term data.
Read more →TSHATaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies reported its Q1 2026 financial results, highlighting progress in its clinical development strategy for TSHA-102, a gene therapy for Rett syndrome. The company reaffirmed alignment with the FDA on its BLA submission pathway and advanced dosing in pivotal trials. Financially, Taysha reported a net loss of $42.4 million, reflecting increased R&D expenses. The company maintains a strong cash position to support its operations through 2028.
Read more →TSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Taysha Gene Therapies has granted restricted stock units (RSUs) to five new employees as part of its 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs, totaling 188,000 shares, will vest over four years, contingent on continued employment. Taysha focuses on AAV-based gene therapies for severe CNS diseases, including Rett syndrome.
Read more →TSHATaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies, Inc. will report its financial results for Q1 2026 on May 6. The company will host a conference call and webcast at 8:30 AM ET to provide a corporate update. Taysha focuses on AAV-based gene therapies for severe monogenic CNS diseases, with its lead program targeting Rett syndrome.
Read more →TSHATaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Taysha Gene Therapies announced new preclinical data for TSHA-102, a gene therapy for Rett syndrome, showing that its self-complementary AAV9 construct significantly enhances MeCP2 protein expression. The data will be presented at the ASGCT Annual Meeting, supporting the ongoing Phase 1/2 REVEAL trials. The findings validate the construct design and highlight the potential for effective CNS delivery.
Read more →TSHATaysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing
Taysha Gene Therapies has reported significant advancements in its clinical trials for TSHA-102, an investigational gene therapy for Rett syndrome, with multiple patients dosed in the pivotal REVEAL trial and FDA clearance for the ASPIRE trial. The company continues to maintain a favorable tolerability profile and is on track to complete dosing by Q2 2026. Financially, however, Taysha reported a net loss of $109 million for 2025, primarily due to escalating research and administrative expenditures. The company remains optimistic about market demand and its registration path with the FDA.
Read more →TSHATaysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies, Inc. announced it will report its full-year 2025 financial results on March 19, 2026. A conference call and webcast will be held at 8:30 AM Eastern Time. The company focuses on AAV-based gene therapies for severe CNS diseases, with a lead program for Rett syndrome.
Read more →About Taysha Gene Therapies, Inc.
Headquarters3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
BIOPHARMAWATCH ELITE PLUS
Trade the next TSHA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime